Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

The continuation of enrollment further expands Clearmind’s international clinical network and strengthens the growing interest in CMND-100 as a potentially groundbreaking treatment for AUD.

New and Updated Clinical Data Summary The Company is currently conducting a multi-center, Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate, for the ...

Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries, has enrolled over 2,000 patients for multiple clinical-stage ADC candidates.

SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary data of two ...

The data indicated early clinical activity and a manageable safety profile with low discontinuation rates. Most common adverse events were gastrointestinal and hematologic toxicities.

Data from the ongoing Phase 1/2 clinical trial (NCT05914116) in patients with heavily pre-treated castration-resistant prostate cancer (CRPC) were presented during an oral session on BNT324/DB-1311, ...